Novartis AG (NOVN) Given a CHF 88 Price Target by Morgan Stanley Analysts

Morgan Stanley set a CHF 88 price target on Novartis AG (VTX:NOVN) in a report issued on Tuesday. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also recently commented on NOVN. S&P Global set a CHF 82 price target on Novartis AG and gave the stock a neutral rating in a report on Tuesday, July 18th. UBS AG set a CHF 76 price target on Novartis AG and gave the stock a neutral rating in a report on Tuesday, July 18th. Sanford C. Bernstein set a CHF 94 price target on Novartis AG and gave the stock a buy rating in a report on Tuesday, July 18th. Deutsche Bank AG set a CHF 81 price target on Novartis AG and gave the stock a neutral rating in a report on Wednesday, July 19th. Finally, Societe Generale set a CHF 91 price target on Novartis AG and gave the stock a buy rating in a report on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of CHF 86.10.

Novartis AG (VTX NOVN) opened at CHF 83.30 on Tuesday. Novartis AG has a twelve month low of CHF 67.80 and a twelve month high of CHF 85.40.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/novartis-ag-novn-given-a-chf-88-price-target-by-morgan-stanley-analysts/1782063.html.

Novartis AG Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.